Hilltop Holdings Inc. Acquires 8,154 Shares of Eli Lilly and Company $LLY

Key Points

• Hilltop Holdings increased its stake in Eli Lilly by 97.9% in Q3, buying 8,154 additional shares to hold 16,480 shares worth about $12.57 million, making LLY its 24th largest holding (≈0.7% of Hilltop's portfolio).
• LLY is heavily institutionally owned (about 82.53%); large investors like Vanguard, Capital Research and Wellington significantly increased positions during the quarter, and Norges Bank and Laurel Wealth made sizable moves as well.
• Eli Lilly has multiple growth catalysts—most notably a planned $3 billion China capacity buildout and expanded Medicare access to key GLP‑1 drugs—alongside strong recent results (quarterly revenue up 42.6% and an EPS beat), supporting a positive analyst consensus ("Moderate Buy").

Hilltop Holdings Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 97.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,480 shares of the company's stock after buying an additional 8,154 shares during the quarter. Eli Lilly and Company accounts for approximately 0.7% of Hilltop Holdings Inc.'s holdings, making the stock its 24th biggest holding. Hilltop Holdings Inc.'s holdings in Eli Lilly and Company were worth $12,574,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Vanguard Group Inc. raised its position in Eli Lilly and Company by 0.7% in the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company's stock worth $61,771,785,000 after purchasing an additional 551,659 shares in the last quarter. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company's stock valued at $11,112,164,000 after purchasing an additional 574,229 shares in the last quarter. Laurel Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company's stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Finally, Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $8,827,714,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Big, long‑term capacity bet in China: Lilly's planned $3 billion, decade‑long buildout in China is being viewed as a strategic way to secure supply, win share in the fast‑growing GLP‑1 market there, and defend margins versus local competitors — a clear revenue runway catalyst. The Real Reason Eli Lilly Is Pouring $3 Billion Into China
• Positive Sentiment: Policy and access tailwinds: CMS expansion of Medicare access to Zepbound and Mounjaro broadens the addressable patient base and reduces a key barrier to volume growth for Lilly’s injectable GLP‑1s. This supports upside to near‑term sales forecasts. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Commercial & product expansion moves: Employer Connect and LillyDirect aim to unlock employer coverage and lower out‑of‑pocket friction for Zepbound, which could materially increase uptake if employers adopt the program. Combined with positive head‑to‑head oral GLP‑1 data for orforglipron, this strengthens the multi‑product growth story. Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
• Positive Sentiment: Clinical pipeline progress: Lilly advanced a Phase‑1 study of eloralintide in high‑risk kidney patients — additional indications or safety/efficacy data can expand uses and support valuation beyond obesity/diabetes franchises. Lilly Advances Eloralintide Study in High-Risk Kidney Patients: What Investors Should Know
• Positive Sentiment: Manufacturing footprint expansion: Smaller regional investments (e.g., Korea, Japan plant expansion) further de‑risk supply and support global launch scale for next‑gen GLP‑1s. These moves reduce disruption risk and help defend market share. Eli Lilly invests $500 million in Korea's biotech growth
• Neutral Sentiment: Valuation / stock structure chatter: Continued outperformance has people speculating about a stock split (accessibility for retail investors), which is psychology‑driven and may influence retail flows but doesn't change fundamentals. 3 Stocks That Could Be Next to Announce a Stock Split
• Negative Sentiment: Safety/supply headline risk: Lilly warned about an unknown impurity found in compounded tirzepatide mixed with vitamin B12 — this raises short‑term PR/regulatory risk and could spur use‑restrictions or additional scrutiny of compounding practices. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Momentum concerns: Some analysts/commentary note weakening trading momentum since November — a reminder that lofty multiples and rate/flow dynamics can pressure the stock if sentiment turns. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November

Eli Lilly and Company Price Performance

LLY opened at $985.10 on Monday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a market capitalization of $930.74 billion, a P/E ratio of 42.92, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company's 50 day simple moving average is $1,037.28 and its 200-day simple moving average is $952.32. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company's revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on LLY shares. Berenberg Bank raised their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a research report on Thursday, February 19th. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Rothschild & Co Redburn lifted their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the company a "neutral" rating in a report on Monday, January 26th. CICC Research boosted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research note on Wednesday, February 11th. Finally, UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,229.59.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.